OneAscent Investment Solutions LLC Invests $307,000 in Bristol Myers Squibb Company (NYSE:BMY)

OneAscent Investment Solutions LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 5,028 shares of the biopharmaceutical company’s stock, valued at approximately $307,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Brighton Jones LLC increased its position in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $13,094,000. United Capital Financial Advisors LLC increased its position in shares of Bristol Myers Squibb by 3.2% during the fourth quarter. United Capital Financial Advisors LLC now owns 180,241 shares of the biopharmaceutical company’s stock valued at $10,194,000 after acquiring an additional 5,615 shares during the last quarter. Finward Bancorp purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $219,000. Finally, Evergreen Capital Management LLC increased its position in shares of Bristol Myers Squibb by 4.2% during the fourth quarter. Evergreen Capital Management LLC now owns 41,113 shares of the biopharmaceutical company’s stock valued at $2,325,000 after acquiring an additional 1,654 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research analyst reports. Citigroup decreased their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Argus raised Bristol Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price for the company. Finally, Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $47.82 on Thursday. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The business has a fifty day moving average price of $47.23 and a 200-day moving average price of $51.66. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The firm has a market capitalization of $97.33 billion, a P/E ratio of 19.28, a PEG ratio of 2.38 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the company earned $2.07 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.